Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
AlphaVax Announces Interim Results From Phase 1 Influenza Vaccine Clinical Trial
August 14th, 2007
AlphaVax, Inc. announced results from an interim review of the data from a Phase I clinical trial of an influenza vaccine that is based on its platform replicon vector technology. The trial is a placebo-controlled, randomized, double-blind, single center study involving 216 healthy volunteers (18-40 years of age). The data are from the analysis of samples taken four weeks after a single dose of the vaccine was administered -- at one of two dosage levels. To date, the vaccine has proven to be safe and very well tolerated. Among those individuals who had pre-vaccination influenza serum antibody titers (measured by hemagglutination inhibition, or "HI") that were below...
Source: Virus Weekly (2007-08-14)
|
